Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.

导出 OA

翻译打印收藏纠错

作者： Paul A,Vanderlaan ^[1] ; Norihiro,Yamaguchi ^[2] ; Erik,Folch ^[3] ; David H,Boucher ^[2] ; Michael S,Kent ^[4] ; Sidharta P,Gangadharan ^[4] ; Adnan,Majid ^[3] ; Michael A,Goldstein ^[2] ; Mark S,Huberman ^[2] ; Olivier N,Kocher ^[1] ; Daniel B,Costa ^[5]

作者单位： Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. ^[1] Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. ^[2] Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States; Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. ^[3] Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. ^[4] Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. Electronic address: dbcosta@bidmc.harvard.edu. ^[5]

关键词 ALK Anaplastic lymphoma kinase Bone specimen Core biopsy EGFR Epidermal growth factor receptor Failure KRAS Lung cancer Molecular testing Never smokers Non-small-cell lung cancer Tumor genotype